First Time Loading...
S

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990

Watchlist Manager
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Watchlist
Price: 175.7 HKD 1.8%
Updated: May 15, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

803.9m
+2 387%
Revenue
Dec 31, 2022 803.9m
Dec 31, 2021 32.3m
-384.7m
+52%
Operating Income
Dec 31, 2022 -384.7m
Dec 31, 2021 -795.2m
-616.1m
+31%
Net Income
Dec 31, 2022 -616.1m
Dec 31, 2021 -889.8m

Earnings Waterfall
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

Revenue
803.9m CNY
Cost of Revenue
-276.8m CNY
Gross Profit
527.1m CNY
Operating Expenses
-911.8m CNY
Operating Income
-384.7m CNY
Other Expenses
-231.4m CNY
Net Income
-616.1m CNY

Income Statement
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Dec-2021 Dec-2022
Revenue
Revenue
32
N/A
804
+2 387%
Gross Profit
Cost of Revenue
(21)
(277)
Gross Profit
12
N/A
527
+4 368%
Operating Income
Operating Expenses
(807)
(912)
Selling, General & Administrative
(88)
(82)
Research & Development
(670)
(797)
Depreciation & Amortization
(65)
(53)
Other Operating Expenses
17
20
Operating Income
(795)
N/A
(385)
+52%
Pre-Tax Income
Interest Income Expense
(95)
(179)
Non-Reccuring Items
(0)
(4)
Pre-Tax Income
(890)
N/A
(567)
+36%
Net Income
Tax Provision
0
(49)
Income from Continuing Operations
(890)
(616)
Net Income (Common)
(890)
N/A
(616)
+31%
EPS (Diluted)
-4.12
N/A
-2.85
+31%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.